Latest news
Ascletis Announces Initiation of Two Phase I Studies in U.S. for the Treatment of Obesity: ASC36 Once-Monthly Injection, an Amylin Receptor Peptide Agonist, and ASC36_35FDC Once-Monthly Injection, a Co-Formulation of ASC36 and GLP-1R/GIPR Peptide - PR NewswirePR Newswire · Mon, 10 Aug 2026 11:00:00 GMTMonthly HIV injections cuts treatment failure in half, offering hope for 126,000 Kenyans - Daily NationDaily Nation · Thu, 06 Aug 2026 03:00:00 GMT